PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgoTM in Healthy Volunteers June 9, 2026 anxiety ONLY AVAILABLE IN PAID PLANS. Originally reported by biospace. Read more Source: https://www.biospace.com/press-releases/puretech-founded-entity-seaport-therapeutics-reports-positive-multiple-ascending-dose-data-from-phase-1-proof-of-concept-trial-of-glyphago-in-healthy-volunteers
